UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 81

Sortiert nach

Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01)

Lung cancer (Amsterdam, Netherlands), 2014-11, Vol.86 (2), p.170-173

2014

Link zum Volltext

Verfügbarkeit prüfen

Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus “at progression” cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis

Therapeutic advances in medical oncology, 2021, Vol.13, p.17588359211006983-17588359211006983

2021

Link zum Volltext

Verfügbarkeit prüfen

First-Line Afatinib plus Cetuximab for EGFR -Mutant Non-Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study

Clinical cancer research, 2021-08, Vol.27 (15), p.4168-4176

2021

Link zum Volltext

Verfügbarkeit prüfen

Drug-induced interstitial lung disease: Indictment for apixaban

Respiratory medicine and research, 2023-11, Vol.84, p.101024-101024, Article 101024

2023

Link zum Volltext

Verfügbarkeit prüfen

Minimal residual disease (MRD) in patients with resected stage I NSCLC: Results of the prospective adjuvant IFCT-0703 trial

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.8526-8526

2021

Link zum Volltext

Verfügbarkeit prüfen

Assessment of preoperative noninvasive ventilation before lung cancer surgery: The preOVNI randomized controlled study

The Journal of thoracic and cardiovascular surgery, 2020-10, Vol.160 (4), p.1050-1059.e3

2020

Link zum Volltext

Verfügbarkeit prüfen

Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small-cell lung cancers: An open phase II study using concurrent cisplatin - oral vinorelbine and radiotherapy (GFPC 08-06)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e20513-e20513

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase II randomized trial of afatinib with or without cetuximab as first-line treatment for EGFR mutated non-small cell lung cancer (NSCLC) patients (IFCT-1503 ACE-Lung)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.9079-9079

2019

Link zum Volltext

Verfügbarkeit prüfen

Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small–cell lung cancers: An open phase II study using concurrent cisplatin–oral vinorelbine and radiotherapy (GFPC 08-06)

Lung cancer (Amsterdam, Netherlands), 2018-07, Vol.121, p.25-29

2018

Link zum Volltext

Verfügbarkeit prüfen

Assessment of palliative care for advanced non-small-cell lung cancer in France: A prospective observational multicenter study (GFPC 0804 study)

Lung cancer (Amsterdam, Netherlands), 2013-11, Vol.82 (2), p.353-357

2013

Link zum Volltext

Verfügbarkeit prüfen

Management of patients with head and neck cancer (HNC) and synchronic stage I or II lung cancer. SYNCHRON GFPC 15-01 study

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e20048-e20048

2017

Link zum Volltext

Verfügbarkeit prüfen

Cost-Effectiveness of Second-Line Chemotherapy for Non-small Cell Lung Cancer: An Economic, Randomized, Prospective, Multicenter Phase III Trial Comparing Docetaxel and Pemetrexed: The GFPC 05-06 Study

Journal of thoracic oncology, 2011-01, Vol.6 (1), p.161-168

2011

Link zum Volltext

Verfügbarkeit prüfen

Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group

Journal of thoracic disease, 2017-10, Vol.9 (10), p.3747-3754

2017

Link zum Volltext

Verfügbarkeit prüfen

Second-Line Oral Chemotherapy (Lomustine, Cyclophosphamide, Etoposide) Versus Intravenous Therapy (Cyclophosphamide, Doxorubicin, and Vincristine) in Patients With Relapsed Small Cell Lung Cancer: A Randomized Phase II Study of GFPC 0501

Clinical lung cancer, 2015-03, Vol.16 (2), p.100-105

2015

Link zum Volltext

Verfügbarkeit prüfen

Pazopanib (P) or placebo in completely resected stage I NSCLC patients: Survival results of the phase II trial IFCT-0703

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.7510-7510

2015

Link zum Volltext

Verfügbarkeit prüfen

Oral Vinorelbine and Cisplatin with Concurrent Radiotherapy After Induction Chemotherapy with Cisplatin and Docetaxel for Patients with Locally Advanced Non-small Cell Lung Cancer: The GFPC 05-03 Study

Journal of thoracic oncology, 2011-02, Vol.6 (2), p.351-357

2011

Link zum Volltext

Verfügbarkeit prüfen

Cost Analysis of Erlotinib Versus Chemotherapy for First-Line Treatment of Non–Small-Cell Lung Cancer in Frail Elderly Patients Participating in a Prospective Phase 2 Study (GFPC 0505)

Clinical lung cancer, 2013-03, Vol.14 (2), p.103-107

2013

Link zum Volltext

Verfügbarkeit prüfen

Cost-utility analysis of maintenance therapy with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502-eco phase III study

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e16560-e16560

2012

Link zum Volltext

Verfügbarkeit prüfen

A Randomized Phase II Trial Assessing in Advanced Non-small Cell Lung Cancer Patients with Stable Disease after Two Courses of Cisplatin-Gemcitabine an Early Modification of Chemotherapy Doublet with Paclitaxel-Gemcitabine Versus Continuation of Cisplatin-Gemcitabine Chemotherapy (GFPC 03-01 Study)

Journal of thoracic oncology, 2009-03, Vol.4 (3), p.364-370

2009

Link zum Volltext

Verfügbarkeit prüfen

PD4-3-7: Multicentric phase II trial of Cisplatin plus Etoposide chemotherapy in advanced Large-Cell Neuro Endocrine Carcinoma of the Lung (LCNEC): preliminary results. Study 03-02 from the “Groupe Francais de Pneumo-Cancerologie (GFPC)

Journal of thoracic oncology, 2007-08, Vol.2 (8), p.S457-S457

2007

Link zum Volltext

Verfügbarkeit prüfen

PD6-3-3: Medical and economical impact of bone metastases in lung cancer patients: a prospective French national, multicentric study (GFPC 06-01 study)

Journal of thoracic oncology, 2007-08, Vol.2 (8), p.S432-S432

2007

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 81

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(62)
Mit Volltextzugriff
(76)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(35)
Life Sciences & Biomedicine
(29)
Humans
(26)
Female
(19)
Male
(19)
Aged
(15)
Oncology
(15)
Life Sciences
(12)
Middle Aged
(12)
Treatment Outcome
(10)
Lung Neoplasms - Pathology
(9)
Adult
(8)
Carcinoma, Non-Small-Cell Lung - Pathology
(8)
Lung Neoplasms - Drug Therapy
(8)
Neoplasm Staging
(8)
Respiratory System
(8)
Aged, 80 And Over
(7)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(7)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(7)
Technology
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01)

Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus “at progression” cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis

Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study

Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study

First-Line Afatinib plus Cetuximab for EGFR -Mutant Non-Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study

Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial

Drug-induced interstitial lung disease: Indictment for apixaban

Minimal residual disease (MRD) in patients with resected stage I NSCLC: Results of the prospective adjuvant IFCT-0703 trial

Assessment of preoperative noninvasive ventilation before lung cancer surgery: The preOVNI randomized controlled study

Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small-cell lung cancers: An open phase II study using concurrent cisplatin - oral vinorelbine and radiotherapy (GFPC 08-06)

Phase II randomized trial of afatinib with or without cetuximab as first-line treatment for EGFR mutated non-small cell lung cancer (NSCLC) patients (IFCT-1503 ACE-Lung)

Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small–cell lung cancers: An open phase II study using concurrent cisplatin–oral vinorelbine and radiotherapy (GFPC 08-06)

Assessment of palliative care for advanced non-small-cell lung cancer in France: A prospective observational multicenter study (GFPC 0804 study)

Management of patients with head and neck cancer (HNC) and synchronic stage I or II lung cancer. SYNCHRON GFPC 15-01 study

Cost-Effectiveness of Second-Line Chemotherapy for Non-small Cell Lung Cancer: An Economic, Randomized, Prospective, Multicenter Phase III Trial Comparing Docetaxel and Pemetrexed: The GFPC 05-06 Study

Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group

Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial “at progression” cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis

Second-Line Oral Chemotherapy (Lomustine, Cyclophosphamide, Etoposide) Versus Intravenous Therapy (Cyclophosphamide, Doxorubicin, and Vincristine) in Patients With Relapsed Small Cell Lung Cancer: A Randomized Phase II Study of GFPC 0501

Pazopanib (P) or placebo in completely resected stage I NSCLC patients: Survival results of the phase II trial IFCT-0703

Oral Vinorelbine and Cisplatin with Concurrent Radiotherapy After Induction Chemotherapy with Cisplatin and Docetaxel for Patients with Locally Advanced Non-small Cell Lung Cancer: The GFPC 05-03 Study

Cost Analysis of Erlotinib Versus Chemotherapy for First-Line Treatment of Non–Small-Cell Lung Cancer in Frail Elderly Patients Participating in a Prospective Phase 2 Study (GFPC 0505)

Cost-utility analysis of maintenance therapy with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502-eco phase III study

A Randomized Phase II Trial Assessing in Advanced Non-small Cell Lung Cancer Patients with Stable Disease after Two Courses of Cisplatin-Gemcitabine an Early Modification of Chemotherapy Doublet with Paclitaxel-Gemcitabine Versus Continuation of Cisplatin-Gemcitabine Chemotherapy (GFPC 03-01 Study)

PD4-3-7: Multicentric phase II trial of Cisplatin plus Etoposide chemotherapy in advanced Large-Cell Neuro Endocrine Carcinoma of the Lung (LCNEC): preliminary results. Study 03-02 from the “Groupe Francais de Pneumo-Cancerologie (GFPC)

PD6-3-3: Medical and economical impact of bone metastases in lung cancer patients: a prospective French national, multicentric study (GFPC 06-01 study)

Suchergebnisse filtern